A pivotal clinical study of LM-030 for the treatment of Netherton Syndrome
Latest Information Update: 21 Nov 2019
At a glance
- Drugs LM 030 (Primary)
- Indications Congenital ichthyosiform erythroderma
- Focus Registrational; Therapeutic Use
Most Recent Events
- 21 Nov 2019 New trial record
- 13 Nov 2019 According to a LifeMax Laboratories media release, the company is ready to enter in this study into clinic.